Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,191 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo: Normal Saline Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence

NCT00611767
View directory record Official record
Conditions
Alcoholism
Interventions
Thiopental, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 30 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 2 Interventional

Semaglutide Therapy for Alcohol Reduction - Tulsa

NCT05891587
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 6, 2026, 11:23 AM EDT
Terminated Phase 2 Interventional Results available

A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder

NCT02234011
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 6, 2026, 11:23 AM EDT
Terminated Phase 4 Interventional Results available

Inflammation-Induced CNS Glutamate Changes in Depression

NCT03004443
View directory record Official record
Conditions
Depression
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

NCT03847909
View directory record Official record
Conditions
Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease
Interventions
DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 6, 2026, 11:23 AM EDT
Not listed Phase 2 Interventional

GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery

NCT04060316
View directory record Official record
Conditions
Sinusitis Chronic
Interventions
GLS-1200, Placebo
Drug
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin and Stress Response in Alcohol Use Disorder

NCT03610633
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 40 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts

NCT02705352
View directory record Official record
Conditions
Ectropion, Skin Neoplasms
Interventions
5-Fluorouracil, Normal saline
Drug · Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

NCT06375512
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ Vaccine (IN001), Placebo, Shingrix
Biological
Lead sponsor
Shenzhen Shenxin Biotechnology Co., Ltd
Industry
Eligibility
50 Years to 69 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 6, 2026, 11:23 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

NCT03862430
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
NanO2TM, Placebo Saline Infusion
Drug
Lead sponsor
NuvOx LLC
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Tucson, Arizona • Orange, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 6, 2026, 11:23 AM EDT
Recruiting Phase 2 Interventional

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

NCT07497399
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
NLY01, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 6, 2026, 11:23 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Wound Infiltration as Part of an Opioid Free Pain Management Pathway Following Cesarean Delivery

NCT03545516
View directory record Official record
Conditions
Pain, Postoperative, Anesthesia, Local, Opioid Use
Interventions
Bupivacaine, Dexmedetomidine, Placebo
Drug
Lead sponsor
Richmond University Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block for COVID-induced Parosmia

NCT06253806
View directory record Official record
Conditions
COVID-19-Induced Parosmia
Interventions
Stellate Ganglion Block, Placebo Sham Injection
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

NCT01666652
View directory record Official record
Conditions
Dengue Fever
Interventions
4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline, 1 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS01E1 adjuvant
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 4 Interventional Results available

Impact of Local Anesthetic Wound Infiltration on Postoperative Pain Following Cesarean Delivery

NCT02829944
View directory record Official record
Conditions
Pain
Interventions
Ropivacaine, Ketorolac, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 6, 2026, 11:23 AM EDT
Withdrawn Phase 2 Interventional

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00715364
View directory record Official record
Conditions
Stroke
Interventions
NTx™-265: rhCG, then rEPO, Saline Placebo
Drug
Lead sponsor
Stem Cell Therapeutics Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Newport Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2011 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Phase 2B Upper Extremity Nerve Block Study

NCT03011333
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, Bupivacaine HCl without epinephrine, Saline Placebo
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Pasadena, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)

NCT00903552
View directory record Official record
Conditions
Seasonal Influenza
Interventions
Influenza VLP Vaccine, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Pembroke Pines, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 6, 2026, 11:23 AM EDT
Terminated Not applicable Interventional Results available

Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation

NCT02498444
View directory record Official record
Conditions
Single Ventricle
Interventions
Treprostinil
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 18 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3

NCT01336699
View directory record Official record
Conditions
Shigella Infection
Interventions
Placebo, WRSs2, WRSs3
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Phase 2 Interventional

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

NCT01119833
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
Interventions
GMI-1070, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
12 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Berkeley, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 6, 2026, 11:23 AM EDT
Completed Not applicable Interventional Results available

Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

NCT01667926
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 6, 2026, 11:23 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Ketorolac Effects on Post-operative Pain and Lumbar Fusion

NCT06513208
View directory record Official record
Conditions
Lumbar Spinal Fusion
Interventions
Ketorolac Tromethamine, Placebo
Drug
Lead sponsor
University of Maryland St. Joseph Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 6, 2026, 11:23 AM EDT